OSR Holdings moves towards major licensing deal for oral cancer immunotherapy

Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones

Gilead delivers groundbreaking HIV prevention drug to Eswatini & Zambia

The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval

GSK's TESARO sues AnaptysBio over alleged breach of cancer drug licence deal

RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia

RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months

Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL

Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments

Sun Pharma settles patent litigation with Incyte

OneSource Specialty Pharma strengthens its board by appointing new directors

These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance

AbbVie and EvolveImmune Therapeutics collaborate to develop next-generation cancer biotherapeutics

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer

Emcure signs agreement with Gilead for manufacture and supply of Lenacapavir

Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries

Dr. Reddy’s signs licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir

Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022